Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 19/20 | 1.00 |
| ▸ | GSK3B | P49841 | 19/20 | 1.00 |
| ▸ | CDK1 | P06493 | 18/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 17/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 17/20 | 1.00 |
| ▸ | CCNB3 | Q8WWL7 | 17/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 12/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 0.66 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.66 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.66 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | PAK4 | O96013 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100624 | 0.82 | GSK3A (0.70) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| Iodide SCHEMBL1779435 | 0.80 | GSK3A (0.69) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| Aloisine SCHEMBL79714 | 0.80 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL490953 | 0.80 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL28753690 | 0.78 | CDK1 (0.71) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL491260 | 0.78 | GSK3A (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL1777822 | 0.77 | GSK3A (0.72) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL490775 | 0.76 | CCNB2 (1.00) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL1777268 | 0.75 | GSK3A (0.69) | GSK3AGSK3BCDK1CCNB2CCNB1 | |
| SCHEMBL12605846 | 0.74 | GSK3A (0.67) | GSK3AGSK3BCDK1CCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106050-B2 | 6-[1-(4-Chlorophenyl)-1-cyclopropyl][5H]pyrrolo[2,3-b]pyrazine; cyclin-dependent kinases and glycogen synthase kinase-3 inhibitor; antiproliferative, anticarcinogenic agent; neurodegenerative disorders; controlling the cell cycle apoptosis, neuronal functions, transcription and exocytosis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-01-31 | — | — | US | disclosed |
| US-20080161312-A1 | Derivatives of Pyrrolo-Pyrazines Having a Kinase Inhibitory Activity and Their Biological Applications | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-07-03 | — | — | US | disclosed |
| EP-1388541-A1 | Pyrrolopyrazines as kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161312-A1 | Derivatives of Pyrrolo-Pyrazines Having a Kinase Inhibitory Activity and Their Biological Applications | CDK2, PLK2, CDK5 | GSK3A 656/4885GSK3B 599/4885CDK1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.